Elanco Animal Health Inc
F:5EA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Elanco Animal Health Inc
F:5EA
|
US |
|
Chemed Corp
F:CXM
|
US |
|
W
|
Westwater Resources Inc
F:UCCP
|
US |
|
Cytek Biosciences Inc
F:8EQ
|
US |
|
S
|
SEB SA
F:GRB
|
FR |
Earnings Calls
Last Earnings Call
Beat and raise: Elanco reported 8% organic constant currency revenue growth in Q2, topping guidance and prompting management to raise full-year outlook for revenue, EBITDA and EPS.
Innovation led: Zenrelia and Credelio Quattro were the biggest growth drivers, while Befrena showed very early demand that was described as stronger than expected.
Margins improved: Gross margin expanded 80 basis points to 58.1%, and management said productivity, mix and Elanco Ascend are helping offset inflation and support further margin gains.
Leverage falling faster: Net leverage reached 3.1x in Q2, and Elanco now expects to end the year at about 3x, better than prior plans.
Pricing resilient: Management said pricing remains responsible across the market, with U.S. pet health pricing accelerating and expected to keep improving in the second half.
Longer runway: The company said its Big 6 innovation products are still early in their growth curves, with significant room ahead in both U.S. and international markets.